New clinical data reveals UCB's investigational pyrimidine nucleoside therapy significantly reduced mortality by 92-94% in patients with thymidine kinase 2 deficiency (TK2d) who developed symptoms before age 12.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.